米力农与多巴酚丁胺治疗心源性休克的比较
该研究为双盲随机对照试验,纳入192例心源性休克患者(每组96例),分别接受米力农或多巴酚丁胺治疗。主要复合终点(院内全因死亡、复苏后心脏骤停、接受心脏移植或机械循环支持、非致死性心梗、神经科医生诊断的TIA或卒中、启动肾脏替代治疗)在米力农组发生47例(49%),多巴酚丁胺组52例(54%),相对风险0.90(95%CI 0.69–1.19,P=0.47),无显著差异。次要终点包括院内死亡、复苏后心脏骤停、机械循环支持、启动肾脏替代治疗等亦无显著差异。结论提示两种正性肌力药物在心源性休克治疗中疗效相当。
要点
- 心源性休克患者中,米力农组主要复合终点事件发生率为49%(47/96),多巴酚丁胺组为54%(52/96),RR 0.90(95%CI 0.69–1.19,P=0.47),无显著差异。
- 院内死亡:米力农组37%,多巴酚丁胺组43%,RR 0.85(95%CI 0.60–1.21),无显著差异。
- 复苏后心脏骤停:米力农组7%,多巴酚丁胺组9%,HR 0.78(95%CI 0.29–2.07)。
- 接受机械循环支持:米力农组12%,多巴酚丁胺组15%,HR 0.78(95%CI 0.36–1.71)。
- 启动肾脏替代治疗:米力农组22%,多巴酚丁胺组17%,HR 1.39(95%CI 0.73–2.67)。
适用人群与场景
- 心源性休克患者,纳入标准及排除标准原文未详细提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 心源性休克患者随机接受米力农或多巴酚丁胺治疗,给药方式为双盲设计;具体剂量、给药途径、频次及目标值原文未提及。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:双盲随机对照试验;样本量192例(每组96例),中心数原文未提及;人群为心源性休克患者;干预为米力农,对照为多巴酚丁胺。
- 主要终点(院内全因死亡、复苏后心脏骤停、接受心脏移植或机械循环支持、非致死性心梗、神经科医生诊断的TIA或卒中、启动肾脏替代治疗的复合终点):米力农组49%(47/96) vs 多巴酚丁胺组54%(52/96),RR 0.90(95%CI 0.69–1.19,P=0.47)。
- 院内死亡:米力农组37% vs 多巴酚丁胺组43%,RR 0.85(95%CI 0.60–1.21)。
- 复苏后心脏骤停:米力农组7% vs 多巴酚丁胺组9%,HR 0.78(95%CI 0.29–2.07)。
- 接受机械循环支持:米力农组12% vs 多巴酚丁胺组15%,HR 0.78(95%CI 0.36–1.71)。
- 启动肾脏替代治疗:米力农组22% vs 多巴酚丁胺组17%,HR 1.39(95%CI 0.73–2.67)。
证据类型、等级与局限
- 证据类型:双盲随机对照试验;证据等级或推荐强度原文未提及;局限:样本量较小(192例),中心数原文未提及,其他局限原文未提及。
对床旁实践的改变
- 在心源性休克患者中,选择米力农或多巴酚丁胺对主要复合终点及关键次要终点无显著影响,床旁决策时两种药物均可考虑,具体选择可基于其他因素(原文未提及具体因素)。
指南或共识出处
- 原文未提及指南或共识名称;研究由Ontario学术健康科学中心替代资助计划创新基金资助,ClinicalTrials.gov注册号NCT03207165。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice.
METHODS: We randomly assigned patients with cardiogenic shock to receive milrinone or dobutamine in a double-blind fashion. The primary outcome was a composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary composite outcome.
RESULTS: A total of 192 participants (96 in each group) were enrolled. The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants (49%) in the milrinone group and in 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95% confidence interval [CI], 0.69 to 1.19; P = 0.47). There were also no significant differences between the groups with respect to secondary outcomes, including in-hospital death (37% and 43% of the participants, respectively; relative risk, 0.85; 95% CI, 0.60 to 1.21), resuscitated cardiac arrest (7% and 9%; hazard ratio, 0.78; 95% CI, 0.29 to 2.07), receipt of mechanical circulatory support (12% and 15%; hazard ratio, 0.78; 95% CI, 0.36 to 1.71), or initiation of renal replacement therapy (22% and 17%; hazard ratio, 1.39; 95% CI, 0.73 to 2.67).
CONCLUSIONS: In patients with cardiogenic shock, no significant difference between milrinone and dobutamine was found with respect to the primary composite outcome or important secondary outcomes. (Funded by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; ClinicalTrials.gov number, NCT03207165.).
参考来源
- Mathew R, Di Santo P, Jung RG, et al. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. N Engl J Med. 2021. PMID: 34347952. doi:10.1056/NEJMoa2026845
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。